RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19

Agency: HEALTH AND HUMAN SERVICES, DEPARTMENT OF
State: District of Columbia
Type of Government: Federal
FSC Category:
  • A - Research and development
NAICS Category:
  • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Posted Date: Sep 10, 2024
Due Date: Oct 18, 2024
Solicitation No: RRPV-24-02-OralVx
Original Source: Please Login to View Page
Contact information: Please Login to View Page
Bid Documents: Please Login to View Page

Description

Follow
RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
Active
Contract Opportunity
Notice ID
RRPV-24-02-OralVx
Related Notice
Department/Ind. Agency
HEALTH AND HUMAN SERVICES, DEPARTMENT OF
Sub-tier
OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
Office
BARDA - ASPR / DAAPPO / BARDA DCMA
General Information
  • Contract Opportunity Type: Special Notice (Original)
  • All Dates/Times are: (UTC-04:00) EASTERN STANDARD TIME, NEW YORK, USA
  • Original Published Date: Sep 10, 2024 07:04 am EDT
  • Original Response Date: Oct 18, 2024 01:00 pm EDT
  • Inactive Policy: 15 days after response date
  • Original Inactive Date: Nov 02, 2024
  • Initiative:
    • None
Classification
  • Original Set Aside:
  • Product Service Code: AN42 - HEALTH R&D SERVICES; HEALTH CARE - OTHER; APPLIED RESEARCH
  • NAICS Code:
    • 541714 - Research and Development in Biotechnology (except Nanobiotechnology)
  • Place of Performance:
    DC
    USA
Description

This solicitation summary is to notify all potential offerors of a Request for Project Proposals (RPP) issued through the Rapid Response Partnership Vehicle (RRPV) Consortium on behalf of the Biomedical Advanced Research and Development Authority (BARDA) titled, "NextGen Oral Formulation Vaccines for COVID-19". The purpose of this effort is to advance oral vaccine platforms and technologies into a proof-of-concept Phase 1 clinical trial, improve our understanding of their potential, and to provide better COVID-19 solutions and bolster preparedness and response against future health security threats. The full RPP and information on joining the consortium can be accessed through the RRPV website at www.rrpv.org.


Attachments/Links
Contact Information
Contracting Office Address
  • O’NEILL HOUSE OFFICE BUILDING
  • WASHINGTON , DC 20515
  • USA
Primary Point of Contact
Secondary Point of Contact


History
  • Sep 10, 2024 07:04 am EDTSpecial Notice (Original)

Related Document

Oct 1, 2024[Special Notice (Updated)] RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
Oct 29, 2024[Special Notice (Updated)] RRPV Solicitation Summary: NextGen Oral Formulation Vaccines for COVID-19
Get Government Bids Like This by Email Receive daily bid alerts that match your keywords, business categories, and target regions.
View Sample Report Start Free Trial

See Also

Establishing a Roster of Pre-...

Solicitation # Details Opening Date Closing Date Other Documents DCSC-26-RFPQ-1 Establishing a Roster

District of Columbia Courts

Due by 9/30/2026

Research Initiatives in Suppo...

Follow Research Initiatives in Support of FHWA Next Generation Structural Materials and Systems

TRANSPORTATION, DEPARTMENT OF

Due by 4/01/2029

Federal Bureau of Investigati...

Follow Federal Bureau of Investigation (FBI) - Office of Chief Information Officer (OCIO)

JUSTICE, DEPARTMENT OF

Due by 5/16/2027

FTA Broad Agency Announcement...

Follow FTA Broad Agency Announcement (FY26) -- "Research Initiatives in Support of Safety,

TRANSPORTATION, DEPARTMENT OF

Due by 10/19/2026

* Disclaimer: This website provides information about bids, requests for proposals (RFPs), or requests for qualifications (RFQs) for convenience only and does not serve as an official public notice. Individuals who wish to respond to or inquire about bids, RFPs, or RFQs should contact the relevant government department directly.